ABSTRACT
gamma-Vinyl GABA, an irreversible inhibitor of GABA transaminase, was administered orally to five patients with catatonic or hebephreno-catatonic schizophrenia. Improvement of psychiatric symptoms was observed in four cases. The results are discussed in relation to previously reported attempts to increase the CNS gabaergic function of patients with schizophrenia.
Subject(s)
4-Aminobutyrate Transaminase/antagonists & inhibitors , Aminocaproates/therapeutic use , Schizophrenia, Catatonic/drug therapy , Schizophrenia, Disorganized/drug therapy , Administration, Oral , Adult , Aminocaproates/adverse effects , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Schizophrenia, Catatonic/psychology , Schizophrenia, Disorganized/psychology , VigabatrinABSTRACT
Oral gamma-vinyl GABA, an irreversible inhibitor of GABA-transaminase, was given to 10 patients with neuroleptic-induced tardive dyskinesia (7 chronic simple schizophrenics and 3 chronic paranoid schizophrenics). Dyskinesia was reduced in 8 of 10 cases. Aggravation of dyskinesia and major psychomotor sedation was observed in two elderly patients with senile dementia. In addition, with regard to schizophrenic symptoms, gamma-vinyl GABA appeared to have beneficial effects on affective withdrawal and retardation, while hallucinations seemed to be aggravated.
